Clark Discusses Agility Clinical Acquisition With ClinicalOMICS


In the latest edition of ClinicalOMICS, Precision for Medicine President Chad Clark elaborates on the recent acquisition of rare and orphan CRO Agility Clinical. Outlining the expansion of Precision’s oncology and rare disease research expertise, Clark also discusses the advantages of deploying Precision’s rapidly growing EU footprint to better serve Agility’s lab, biomarker, and clinical development needs.

To read the complete article, please click here.


Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.